Form 4: Shattuck Labs CBO Reports Stock Transactions

Shattuck Labs' CBO, Casi DeYoung, reported a grant of 381,600 stock options and a tax-related sale of 5,699 shares.

Summary

• Casi DeYoung, Chief Business Officer of Shattuck Labs, Inc. (STTK), reported changes in beneficial ownership.
• On January 10, 2026, DeYoung disposed of 5,699 shares of common stock at a price of $4.75 per share, likely to satisfy tax withholding obligations related to equity compensation.
• Following this disposition, DeYoung directly beneficially owned 75,766 shares of common stock.
• On the same date, DeYoung was granted an option to purchase 381,600 shares of the Issuer's common stock with an exercise price of $4.75 per share.
• One quarter of these options will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, contingent on continued service.
• The options have an expiration date of January 10, 2036.
• After this transaction, DeYoung directly beneficially owned 381,600 derivative securities (options).

Sentiment

Score: 7

Explanation: The filing reports a significant grant of stock options to a key executive, indicating continued alignment of interests with shareholders, alongside a routine disposition of shares for tax purposes. This is generally viewed as a neutral to slightly positive event for corporate governance and executive retention.

Positives

• The grant of 381,600 stock options to the Chief Business Officer aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The options have a 10-year expiration date, providing a long-term incentive horizon.

Negatives

• The disposition of 5,699 shares, even for tax purposes, represents a reduction in the direct common stock holdings of a key executive.

Risks

• No specific company-wide risks are detailed in this Form 4 filing, which focuses on insider transactions.

Future Outlook

The filing indicates a future vesting schedule for the granted stock options, with one quarter vesting on January 10, 2027, and the remainder vesting monthly through January 10, 2030, subject to the Chief Business Officer's continued service.

Industry Context

This filing reflects a routine executive compensation event common in the biotechnology and pharmaceutical industries, where equity-based incentives are a standard component of remuneration to attract, retain, and motivate key personnel. The grant of stock options is a typical mechanism to align executive performance with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as a significant component of executive compensation is a standard practice across the biotech and broader technology sectors, aiming to align executive incentives with long-term company performance.
• The vesting schedule, with a multi-year period, is typical for executive equity awards, promoting long-term retention and sustained performance.
• The disposition of shares to cover tax withholding obligations upon the vesting or exercise of equity awards is a common and expected transaction for executives receiving such compensation.

Stakeholder Impact

• Shareholders: The grant of stock options to a key executive can be seen as a positive for shareholders, as it aligns the executive's financial interests with the company's long-term stock performance.
• Employees (Executive): The Chief Business Officer benefits from increased equity ownership and long-term incentive potential.

Next Steps

• One quarter of the granted stock options will vest on January 10, 2027.
• The remaining three quarters of the options will vest in equal monthly installments through January 10, 2030.

Key Dates

Recommendation

This Form 4 details routine executive compensation and tax-related share dispositions. While the grant of options aligns executive interests with shareholders, it does not provide new fundamental information to alter an investment thesis. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Shattuck Labs, STTK, Form 4, Insider Transaction, Stock Options, Equity Compensation, Casi DeYoung, Chief Business Officer, Beneficial Ownership